title: Pilot Study of Intrahepatic Artery Chemotherapy in Combination with Sorafenib in Hepatocellular Carcinoma.
abstract: OBJECTIVE
  Sorafenib and chemoembolization of the liver (TACE) have both produced increased survival in hepatocellular carcinoma (HCC). Some patients cannot tolerate TACE due to portal vein thrombosis or risk of liver failure. In this pilot trial, we aimed to combine intrahepatic infusion (IA) of cisplatin or carboplatin with sorafenib for unresectable HCC.
  
  
  METHODS
  Patients with Child's A or early B received IA cisplatin or carboplatin every 6 weeks with oral sorafenib. MRI/CT scans were performed every 6 weeks.
  
  
  RESULTS
  Eleven patients were accrued. Of 10 evaluable patients, 6 had clinical benefit (4 partial responses for 2+, 3+, 8+ and 18 months, 2 minor responses). Two patients were down-staged enough for ablation therapy or liver transplant and remain free of disease for 32+ and 36+ months. Toxicity was generally tolerable.
  
  
  CONCLUSIONS
  Preliminary results are encouraging and this combination may down-stage some patients with unresectable disease.
authors.affiliation: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, U.S.A. Miami VA Healthcare System, Miami, FL, U.S.A.
authors.forename: V Y
authors.initials: VY
authors.lastname: Dinh
authors.affiliation: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, U.S.A. Miami VA Healthcare System, Miami, FL, U.S.A.
authors.forename: Shivank
authors.initials: S
authors.lastname: Bhatia
authors.affiliation: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, U.S.A.
authors.forename: Govindarajan
authors.initials: G
authors.lastname: Narayanan
authors.affiliation: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, U.S.A.
authors.forename: Jose
authors.initials: J
authors.lastname: Yrizarry
authors.affiliation: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, U.S.A. Miami VA Healthcare System, Miami, FL, U.S.A.
authors.forename: Niramol
authors.initials: N
authors.lastname: Savaraj
authors.affiliation: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, U.S.A.
authors.forename: Christopher
authors.initials: C
authors.lastname: O'Brien
authors.affiliation: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, U.S.A.
authors.forename: Paul
authors.initials: P
authors.lastname: Martin
authors.affiliation: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, U.S.A. lfeun@med.miami.edu.
authors.forename: Lynn
authors.initials: L
authors.lastname: Feun
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000821:virology; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006499:Hepatic Artery; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives; D010671:Phenylurea Compounds / Q000008:administration & dosage; D010865:Pilot Projects; D000077157:Sorafenib
chemical_list: D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; D016190:Carboplatin; D002945:Cisplatin
keywords: Intrahepatic chemotherapy; hepatocellular cancer; sorafenib